MiMedx Group, Inc. (MDXG)
| Market Cap | 1.08B |
| Revenue (ttm) | 363.77M |
| Net Income (ttm) | 32.17M |
| Shares Out | 147.96M |
| EPS (ttm) | 0.21 |
| PE Ratio | 34.42 |
| Forward PE | 25.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 859,529 |
| Open | 7.28 |
| Previous Close | 7.23 |
| Day's Range | 7.24 - 7.45 |
| 52-Week Range | 5.47 - 10.14 |
| Beta | 1.79 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+64.95%) |
| Earnings Date | Jul 30, 2025 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The co... [Read more]
Financial Performance
In 2024, MiMedx Group's revenue was $348.88 million, an increase of 8.52% compared to the previous year's $321.48 million. Earnings were $42.42 million, a decrease of -8.94%.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price target is $12.0, which is an increase of 64.95% from the latest price.
News
MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Douglas C. Rice - Chief Financial Officer Joseph H.
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results
Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06,...
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the compan...
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second qu...
MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026
New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following in...
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securit...
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)
Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company'...
MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Matthew Notarianni - Head, IR Joseph Capper - CEO & Director Doug Rice - CFO Conferenc...
MIMEDX Announces First Quarter 2025 Operating and Financial Results
Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17...
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quar...
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference
MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Healt...
MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer ...
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results
Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted E...
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NE...
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug...
MIMEDX Announces Third Quarter 2024 Operating and Financial Results
Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05 , Respectively Third Quarter Adjusted EBITDA was $1...
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third qua...
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patien...
MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research MARIETTA, Ga., Oct. 01,...
EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"
10 Former MiMedx Employees In Non-Compete Suit Fight Back Against MiMedx Schemes to "Bilk Medicare" and "Incentivize Fraud" in Counterclaims Filed by Mintz Attorneys MARIETTA, Ga. , Sept. 11, 2024 /PR...
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga. , Sept. 4, 2024 /PRNewsw...
DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga. , Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants wh...
MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Ri...
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products Limited market release marks first xenograft addition to Company's portfolio of lead...